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The link between Akt activation and gluconeogenic repression remains unclear, despite many years of inves-
tigation and remarkable progress. Rodgers and colleagues now introduce us to the Clk2 kinase, an Akt
substrate that can directly phosphorylate and inhibit PGC-1a, blunting hepatic glucose production.A decade after its cloning, PGC-1a’s role
as a master regulator of mitochondrial
biogenesis and gluconeogenesis is undis-
puted (Rodgers et al., 2008). Initially iden-
tified as a cofactor for the nuclear
receptor PPARg (Puigserver et al., 1998),
PGC-1a is the founding member of a small
family of coactivators (which includes
PGC-1b and PRC) that are involved in
the regulation of metabolism in general
and mitochondrial function in particular
(Rodgers et al., 2008). Recent work has
shown that PGC-1a activity is controlled
by an ever-increasing number of post-
translational modifications (PTMs). These
PTMs are induced by multiple hormonal,
metabolic, and stress signals and can be
considered integrative nodes that fine-
tune the activity of PGC-1a (see Figure 1).
In this regard, PGC-1a can be phosphor-
ylated on different residues by several
kinases, including p38MAPK, AMPK, and
Akt (Rodgers et al., 2008). Similar PTMs,
however, do not necessarily have similar
effects on PGC-1a. For example, phos-
phorylation of PGC-1a on Thr177 and
Ser538 by AMPK activates PGC-1a (Ja¨ger
et al., 2007), whereas phosphorylation by
Akt on Ser570 is inhibitory (Li et al., 2007)
(Figure 1). PGC-1a activity is also regu-
lated by acetylation of up to 13 lysine
residues (Rodgers et al., 2005). When
acetylated by GCN5 (Lerin et al., 2006),
PGC-1a activity is low, whereas deacety-
lation by SIRT1 robustly increases its
activity (Rodgers et al., 2008). In this issue
of Cell Metabolism, Rodgers et al. deepen
our knowledge of PGC1a regulation by
finding a new modification that critically
controls PGC-1a’s ability to regulate the
gluconeogenic gene program.
During fasting, PGC-1a promotes the
expression of gluconeogenic genes by
coactivating a number of transcription
factors, including the FOXOs, HNF4a, or
CREB. This implies that PGC-1a activity6 Cell Metabolism 11, January 6, 2010 ª2010has to be quickly turned off upon food
intake, an effect that could be achieved if
PGC-1a was responsive to insulin. Now,
work by Rodgers et al. confirms that this
is, in fact, the case (Rodgers et al., 2010).
First, the authors identify Clk2 (Cdc2-like
kinase) as an Akt target. Clk2 belongs to
an evolutionary conserved family of
protein kinases that phosphorylate SR
domains of splicing factors (Colwill et al.,
1996). The function and regulation of the
Clks, however, are still largely a mystery.
The Puigserver lab now demonstrates
that Clk2 protein levels are exquisitely
regulated during fasting/refeeding cycles
through changes in Clk2 protein stability.
Insulin action increases Clk2 protein
stability and therefore activity through
phosphorylation of Clk2 on Thr343 by Akt.
Furthermore, Clk2 can also autophos-
phorylate, amplifying and perpetuating
Clk2 activity once Akt activity is shut
down. Looking downstream, Rodgers
et al. show that Clk2 phosphorylates the
SR domain of PGC-1a. This domain is
pivotal to PGC-1a function, as it mediates
insulin responsiveness, contains an Akt
phosphorylation site (Li et al., 2007), and
constitutes the region of interaction with
FOXO transcription factors (Puigserver
et al., 2003). Phosphorylation of the SR
domain by Clk2 renders PGC-1a unable
to specifically coactivate FOXO and
other nuclear receptors controlling the
gluconeogenic program. Of interest, SR
phosphorylation by Clk2 does not affect
PGC-1a coactivation of transcription
factors involved in mitochondrial biogen-
esis, such as NRF-1. The suppressive
role of Clk2 on hepatic glucose output is
elegantly supported by data showing
that overexpression of Clk2 induces
fasting hypoglycemia and ameliorates
hyperglycemia in db/db mice. Based on
this observation, the authors postulate
that Clk2 acts as a ‘‘long-acting’’ insulin-Elsevier Inc.induced gluconeogenic repressor that
sustains the inhibition of glucose produc-
tion during refeeding once Akt is downre-
gulated.
It is interesting to note that Akt can also
inhibit PGC-1a through direct phosphory-
lation on Ser570 (Li et al., 2007), a residue
located in the SR domain, the region that
is also phosphorylated by Clk2. The fact
that two effector kinases promote similar
actions raises the question of whether
the observed effects are simply due to
regulation of Akt by Clk2. It was therefore
reassuring to see that Clk2 does not
phosphorylate Ser570, the residue tar-
geted by Akt (Li et al., 2007). In fact,
Clk2 can repress the activity of the PGC-
1a S570A mutant, which is not responsive
to Akt, indicating that Akt and Clk2 may
use different mechanisms to inhibit
PGC-1a’s gluconeogenic activity. Akt
and Clk2 could therefore inhibit PGC-1a
in a complementary fashion in different
physiological settings and phases, a
point that warrants future investigation.
Furthermore, to ensure robust repression
of gluconeogenesis, Akt activation simul-
taneously impacts on diverse gluconeo-
genic regulators other than PGC-1a,
such as FOXO1 and CRTC2. Hence, it
would not be surprising if the actions of
Clk2 expand beyond PGC-1a.
Though this work constitutes a major
leap in our understanding of the regulation
of glucose production, it also raises new
questions. For example, cross-regulation
between Clk2 and Akt might indeed
exist, as the authors show that artificial
modulation of Clk2 levels leads to an
inverse effect on Akt activity. For example,
knockdown of Clk2 increases Akt Ser473
and PGC-1a Ser570 phosphorylation yet
results in an apparently contradictory in-
crease in PGC-1a activity. This feedback
loop between Clk2 and Akt makes the
physiological implications of manipulating
Figure 1. Posttranslational Modifications of PGC-1a
The architecture of PGC-1a shows how posttranslational modifications (PTMs) occur across the span of
the different protein domains. The table below summarizes the relationship between the various modifica-
tions and their biological output. A, acetylation; G, O-linked b-N-acetylglucosamine; M, methylation; P,
phosphorylation; S, sumoylation; SR, serine-arginine-rich domain; RNA, RNA-binding domain.
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Another interesting point will be to under-
stand how Clk2 is shut down once Akt trig-
gers Clk2 autoregulation. It will also be
challenging to elucidate the implications
of the insulin/Akt/Clk2 axis in nongluco-
neogenic tissues. Answering these ques-
tions might help to further validate Clk2
as a pharmacological target, as the results
by Rodgers et al. suggest that artificial
activation of liver Clk2 could be used as
a glucose-lowering strategy.
Altogether, the phosphorylation of
PGC-1a by Clk2 adds yet another layer
of regulation to the biology of PGC-1a. Itwill be interesting to understand the
crosstalk between the wide spectrum of
PGC-1a PTMs. The fact that the phos-
phorylation of PGC-1a by AMPK regu-
lates PGC-1a deacetylation (Canto´ et al.,
2009) indicates that such interactions
might not happen independently but,
rather, act in coordination. Also, the sheer
variety of PTMs calls into question their
role as global functional switches; rather,
they may constitute a fine-tuning mecha-
nism that drives PGC-1a activity toward
specific gene sets by, for example, allow-
ing or obstructing interaction with spe-
cific transcription factors. The fact thatCell MetabolismClk2 phosphorylation only attenuates the
action of PGC-1a on gluconeogenesis,
leaving its effect on mitochondrial genes
intact, supports this line of thinking.
Consequently, the alteration of specific
PTMs in PGC-1a might be an attractive
strategy in the management of disease,
as it would allow targeting of selective
gene sets and functions, refining current
concepts aimed at inducing PGC-1a
expression.REFERENCES
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